Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
46.15
-0.08 (-0.17%)
At close: Aug 13, 2025, 4:00 PM
45.75
-0.40 (-0.87%)
After-hours: Aug 13, 2025, 7:56 PM EDT
Avidity Biosciences Stock Forecast
Stock Price Forecast
According to 15 professional analysts, the 12-month price target for Avidity Biosciences stock ranges from a low of $53 to a high of $96. The average analyst price target of $68.4 forecasts a 48.21% increase in the stock price over the next year.
Price Target: $68.40 (+48.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avidity Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 6 | 6 | 6 | 7 | 7 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 14 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $75 | Buy | Maintains | $70 → $75 | +62.51% | Aug 8, 2025 |
| Barclays | Barclays | Buy Maintains $59 → $62 | Buy | Maintains | $59 → $62 | +34.34% | Aug 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $75 | Strong Buy | Maintains | $75 | +62.51% | Aug 8, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $55 | Strong Buy | Initiates | $55 | +19.18% | Jul 10, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $96 | Buy | Reiterates | $96 | +108.02% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
6.88M
from 10.90M
Decreased by -36.87%
Revenue Next Year
20.37M
from 6.88M
Increased by 196.18%
EPS This Year
-4.04
from -2.89
EPS Next Year
-4.52
from -4.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.8M | 81.6M | 770.0M |
| Avg | 6.9M | 20.4M | 322.0M |
| Low | n/a | n/a | 74.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 27.0% | 1,086.0% | 3,679.2% |
| Avg | -36.9% | 196.2% | 1,480.3% |
| Low | - | - | 265.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.85 | -2.78 | -0.38 |
| Avg | -4.04 | -4.52 | -3.22 |
| Low | -5.25 | -5.53 | -4.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.